脓毒症与非脓毒症危重患者的健康相关结局比较
该研究基于一项大型多中心临床试验的数据,纳入3537例符合条件的危重患者,获取3442例(97.3%)的链接数据,采用倾向评分匹配将806例脓毒症患者与806例非脓毒症患者进行匹配。匹配后,两组幸存者在行动能力、自我照顾、日常活动、疼痛/不适及焦虑/抑郁方面报告问题的比例均无显著差异。2年生存率亦无显著差异:脓毒症组482/792(60.9%)vs 非脓毒症组485/799(60.7%)(HR 1.01,95%CI 0.86-1.18,p=0.94)。但脓毒症患者初始ICU入住时间(10.1±11.9 vs 8.0±9.8天,p<0.0001)和住院时间(22.8±21.2 vs 19.1±19.0天,p=0.0003)更长,ICU费用更高(A$43,345±46,263 vs A$34,844±38,281,平均差A$8,501,95%CI A$4,342-12,660,p<0.001),至2年的总住院费用亦更高(A$74,120±60,750 vs A$65,806±59,856,p=0.005)。结论提示脓毒症危重患者医疗资源使用和费用更高,但生存率和健康相关生活质量与非脓毒症匹配患者相似。
要点
- 匹配后脓毒症与非脓毒症危重患者2年生存率无显著差异:482/792(60.9%)vs 485/799(60.7%),HR 1.01(95%CI 0.86-1.18),p=0.94。
- 匹配后两组幸存者6个月健康相关生活质量各维度报告问题的比例均无显著差异,如行动能力37.8% vs 38.7%(p=0.86)。
- 脓毒症患者初始ICU入住时间更长:10.1±11.9 vs 8.0±9.8天(p<0.0001),住院时间亦更长:22.8±21.2 vs 19.1±19.0天(p=0.0003)。
- 脓毒症患者ICU费用更高:A$43,345±46,263 vs A$34,844±38,281,平均差A$8,501(95%CI A$4,342-12,660),p<0.001。
- 脓毒症患者至2年总住院费用更高:A$74,120±60,750 vs A$65,806±59,856,p=0.005。
适用人群与场景
- 纳入一项大型多中心临床试验中的危重成人患者,分为脓毒症组和非脓毒症组,最终分析3442/3537例(97.3%)有链接数据的患者。
研究设计与关键结果
- 研究类型为对一项大型多中心临床试验患者进行的倾向评分匹配分析,获取3442/3537例(97.3%)合格患者的链接数据,将806/905例(89.0%)脓毒症患者与806/2537例(31.7%)非脓毒症患者进行匹配。
- 匹配后幸存者6个月健康相关生活质量各维度报告问题比例:行动能力37.8% vs 38.7%(p=0.86),自我照顾24.7% vs 26.0%(p=0.44),日常活动44.5% vs 46.8%(p=0.28),疼痛/不适42.4% vs 41.6%(p=0.54),焦虑/抑郁36.9% vs 37.7%(p=0.68),均无显著差异。
- 2年生存率无显著差异:脓毒症组482/792(60.9%)vs 非脓毒症组485/799(60.7%),HR 1.01(95%CI 0.86-1.18),p=0.94。
- 初始ICU入住时间脓毒症组10.1±11.9天 vs 非脓毒症组8.0±9.8天(p<0.0001),住院时间22.8±21.2天 vs 19.1±19.0天(p=0.0003)。
- ICU费用脓毒症组A$43,345±46,263(€35,109±35,043)vs 非脓毒症组A$34,844±38,281(€28,223±31,007),平均差A$8,501(€6,885),95%CI A$4,342-12,660(€3,517-10,254),p<0.001。
- 至2年总住院费用脓毒症组A$74,120±60,750(€60,037±49,207)vs 非脓毒症组A$65,806±59,856(€53,302±48,483),p=0.005。
证据类型、等级与局限
- 证据类型:对一项大型多中心临床试验患者进行的倾向评分匹配分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒症危重患者医疗资源使用和费用更高,但生存率和健康相关生活质量与非脓毒症匹配患者相似。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To determine differences in health-related quality of life (HRQoL), survival and healthcare resource use of critically ill adults with and without sepsis.
METHODS: We conducted a primary propensity score matched analysis of patients with and without sepsis enrolled in a large multicentre clinical trial. Outcomes included HRQoL at 6 months, survival to 2 years, length of ICU and hospital admission and cost of ICU and hospital treatment to 2 years.
RESULTS: We obtained linked data for 3442 (97.3%) of 3537 eligible patients and matched 806/905 (89.0%) patients with sepsis with 806/2537 (31.7%) without. After matching, there were no significant differences in the proportion of survivors with and without sepsis reporting problems with mobility (37.8% vs. 38.7%, p = 0.86), self-care (24.7% vs. 26.0%, p = 0.44), usual activities (44.5% vs. 46.8%, p = 0.28), pain/discomfort (42.4% vs. 41.6%, p = 0.54) and anxiety/depression (36.9% vs. 37.7%, p = 0.68). There was no significant difference in survival at 2 years: 482/792 (60.9%) vs. 485/799 (60.7%) (HR 1.01, 95% CI 0.86-1.18, p = 0.94). The initial ICU and hospital admission were longer for patients with sepsis: 10.1 ± 11.9 vs. 8.0 ± 9.8 days (p < 0.0001) and 22.8 ± 21.2 vs. 19.1 ± 19.0 days, (p = 0.0003) respectively. The cost of ICU admissions was higher for patients with sepsis: A$43,345 ± 46,263 (€35,109 ± 35,043) versus 34,844 ± 38,281 (€28,223 ± 31,007), mean difference $8501 (€6885), 95% CI $4342-12,660 (€3517 ± 10,254), p < 0.001 as was the total cost of hospital treatment to 2 years: A$74,120 ± 60,750 (€60,037 ± 49,207) versus A$65,806 ± 59,856 (€53,302 ± 48,483), p = 0.005.
CONCLUSIONS: Critically ill patients with sepsis have higher healthcare resource use and costs but similar survival and HRQoL compared to matched patients without sepsis.
参考来源
- Thompson K, Taylor C, Jan S, et al. Health-related outcomes of critically ill patients with and without sepsis. Intensive Care Med. 2018. PMID: 29951846. doi:10.1007/s00134-018-5274-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。